EGFR and non-small cell lung carcinoma: In conclusion, our study strengthens the evidence on the comparable efficacy of lazertinib with osimertinib and the potential beneficial effect on the survival in patients with advanced EGFR T790M-positive NSCLC who experienced disease progression following EGFR-TKI, which was shown in a single-arm trial.